Procept Biorobotics Stock

Procept Biorobotics EBIT

The EBIT of Procept Biorobotics (PRCT) as of Aug 5, 2026 is -103.86 M USD. In the previous year, EBIT was -96.61 M USD — a change of 7.50% (lower).

EBIT

-103.86 MUSD

YoY

7.50%

Last updated:

In 2026, Procept Biorobotics's EBIT was -103.86 M USD, a 7.50% increase from the -96.61 M USD EBIT recorded in the previous year.

The Procept Biorobotics EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2023
-109.17 base
Jan 1, 2024
-96.61 base
Jan 1, 2025
-103.86 base
Jan 1, 2026 (e)
185.03 base
Jan 1, 2027 (e)
228.34 base
Jan 1, 2028 (e)
273.69 base
Jan 1, 2029 (e)
317.31 base
Jan 1, 2030 (e)
370.05 base
YEAREBIT (M USD)
2030 est 370.05
2029 est 317.31
2028 est 273.69
2027 est 228.34
2026 est 185.03
2025 -103.86
2024 -96.61
2023 -109.17
2022 -84.47
2021 -54.16
2020 -47.94
2019 -43.55
Access this data via the Eulerpool API

Procept Biorobotics Revenue

Procept Biorobotics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
132.46 M USD
-109.17 M USD
-105.90 M USD
Jan 1, 2024
220.31 M USD
-96.61 M USD
-91.41 M USD
Jan 1, 2025
304.47 M USD
-103.86 M USD
-95.57 M USD
Jan 1, 2026 (e)
397.47 M USD
185.03 M USD
-85.40 M USD
Jan 1, 2027 (e)
490.49 M USD
228.34 M USD
-49.64 M USD
Jan 1, 2028 (e)
587.90 M USD
273.69 M USD
-33.29 M USD
Jan 1, 2029 (e)
681.61 M USD
317.31 M USD
-10.00 M USD
Jan 1, 2030 (e)
794.90 M USD
370.05 M USD
35.55 M USD

Procept Biorobotics Margins

Procept Biorobotics stock margins

The Procept Biorobotics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Procept Biorobotics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Procept Biorobotics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
53.64 %
-82.42 %
-79.95 %
Jan 1, 2024
62.23 %
-43.85 %
-41.49 %
Jan 1, 2025
64.45 %
-34.11 %
-31.39 %
Jan 1, 2026 (e)
64.45 %
46.55 %
-21.49 %
Jan 1, 2027 (e)
64.45 %
46.55 %
-10.12 %
Jan 1, 2028 (e)
64.45 %
46.55 %
-5.66 %
Jan 1, 2029 (e)
64.45 %
46.55 %
-1.47 %
Jan 1, 2030 (e)
64.45 %
46.55 %
4.47 %

Procept Biorobotics Stock analysis

What does Procept Biorobotics do? PROCEPT BioRobotics Corp (PROCEPT) is a California-based medical technology company specializing in the development of robotic technologies for urological surgery. History: PROCEPT was founded in 2013 by Dr. Chin and his group at Johns Hopkins University School of Medicine. They developed a novel technology that had the potential to revolutionize the treatment of prostate cancer. PROCEPT used a robust Intuitive Surgical platform and developed a novel tissue classification technology that allows surgeons to operate with accuracy and safety. The first system, called AquaBeam®, was approved by the US Food and Drug Administration (FDA) in 2018 and has since been in use in Europe and the US. Business: PROCEPT aims to improve urological surgery through the use of robotic technologies, thereby increasing patient safety and care. The company focuses on the development and commercialization of robotic systems for the treatment of prostate cancer and other urological diseases. Products: PROCEPT has developed Aquablation®, a robotic system for the treatment of prostate cancer. It is a minimally invasive technology that uses high-precision waterjet cutting (accuracy reduced to millimeters) to remove cancerous tissue quickly, effectively, and accurately. The technology can also be used in surgical procedures on the bladder, urethra, and other urological organs. Divisions: PROCEPT has a broad portfolio of services and products in the field of urological surgery. The AquaBeam® technology is the first system developed to treat malignant prostate tumors using robotic technologies. The technology is used in hospitals, clinics, and medical facilities worldwide. In addition, PROCEPT offers training and support for surgeons and medical personnel. Conclusion: PROCEPT BioRobotics Corp is an emerging medical technology company specializing in robotics-based urological surgery. The AquaBeam® technology is an innovative, robotic technology for the treatment of prostate cancer. The company is on its way to revolutionizing urological surgery and making a significant contribution to improving healthcare. Procept Biorobotics is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Procept Biorobotics's EBIT

Procept Biorobotics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Procept Biorobotics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Procept Biorobotics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Procept Biorobotics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Procept Biorobotics stock

EBIT of Procept Biorobotics is -103.86 M USD in 2026.

EBIT of Procept Biorobotics changed from -96.61 M USD to -103.86 M USD, representing a 7.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Procept Biorobotics since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Procept Biorobotics historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Procept Biorobotics

All Key Metrics — Procept Biorobotics